Novo Nordisk (NVON) AI Stock Analysis

Novo Nordisk

(BMV:NVON)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Exceptional growth and profitabilityNovo combines rapid revenue expansion with unusually high profitability, indicating strong product economics and pricing power in chronic-care medicines. These margins can support substantial reinvestment in manufacturing, commercial expansion and research while providing resilience through normal business-cycle fluctuations.

Negative Factors

Challenging 2026 outlookManagement’s flat-to-declining 2026 outlook signals that near-term growth is being pressured by lower realized prices, competition, coverage reductions and semaglutide exclusivity losses. These forces could persist across the next several quarters and make recent exceptional growth harder to sustain.

Novo Nordisk (NVON) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 176.43B
Dividend Yield: 4.10%
Average Volume (3M): 6,468
Price to Earnings (P/E): 10.1
Beta (1Y): 0.07
Revenue Growth: 2.82%
EPS Growth: 2.08%
Country: Mexico
Employees: 68,794
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Novo Nordisk Business Overview & Revenue Model

Company Description

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Af...

Novo Nordisk Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:-7.67%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call was broadly constructive, supported by strong GLP-1 volume growth, rapid Wegovy pill uptake in the U.S. and international markets, continued pipeline advancement, Q2 sales growth of 7%, operating profit growth of 11%, and transformation savings ahead of plan. However, the company faces material headwinds from lower realized prices, declining gross margin, U.S. competition and coverage pressure, semaglutide loss of exclusivity, declining international market share, and the unsuccessful ZEUS cardiovascular outcomes trial. Overall, the highlights significantly outweigh the lowlights, although management characterized 2026 as a challenging year.

Positive Updates

Expanded Patient Reach

Novo Nordisk is serving more than 46 million people living with obesity and diabetes. The company is treating almost 70% more people living with obesity than a year ago, with nearly 5 million people using its obesity treatments.

Negative Updates

ZEUS Trial Failed to Reduce Cardiovascular Events

The ZEUS trial of ziltivekimab did not demonstrate a reduction in major adverse cardiovascular events, with a hazard ratio of 0.99, despite target engagement and expected reductions in free IL-6 and hsCRP.

Company Guidance

For 2026, adjusted sales growth is now expected to be 0% to -6% at constant exchange rates, and adjusted operating profit is now expected to be 0% to -6% at constant exchange rates; the outlook includes continued volume penetration for GLP-1 treatments and market expansion in International Operations, negative impacts from the compound patent expiry of the semaglutide molecule in certain markets, intensifying competition and negative impact from reduced obesity medication coverage in Medicaid in U.S. Operations, and further lower realized prices linked to investments in market access, amplified by the most favored nations agreements with the U.S. administration. The company is ahead of plan to deliver the DKK 8 billion of savings from the company-wide transformation, and expects a U.S. decision for CagriSema in obesity at the end of 2026, with a potential launch in 2027; the phase II trial for the triple agonist is expected to read out in the second half of 2027, UBT251 is expected to read out by the end of 2027, and 2027 guidance will come in February next year.

Novo Nordisk Risk Analysis

Novo Nordisk disclosed 17 risk factors in its most recent earnings report. Novo Nordisk reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Novo Nordisk Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:NVON against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LLY	81Outperform	$1.33T	45.89	83.65%	0.47%	45.51%	50.48%
AMGN	75Outperform	$251.94B	28.73	89.32%	2.13%	9.89%	31.69%
NVS	72Outperform	$297.25B	31.19	24.24%	2.95%	1.64%	-28.72%
SNY	71Outperform	$107.18B	24.39	5.52%	5.46%	23.68%	-30.90%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:NVON and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:NVON	Novo Nordisk	746.28	-132.25	-15.05%
AMGN	Amgen Inc	466.01	177.71	61.64%
LLY	Eli Lilly And Company	1417.54	526.63	59.11%
MRK	Merck & Company	149.52	69.38	86.58%
NVS	Novartis AG	160.79	39.31	32.36%
SNY	Sanofi SA	44.34	-3.79	-7.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Novo Nordisk AI Stock Analysis